News

Gland Pharma (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BRIDION� Injection of Merck Sharp & Dohme LLC. The Product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.

Gland Pharma will hold a meeting of the Board of Directors of the Company on 10 August 2026.

Gland Pharma announced that Satyanarayana Murthy Chavali, DIN: 00142138, Independent Director of the Company has tendered resignation to his directorship in the Company with effect from 15 June 2026.

Gland Pharma has allotted 2,03,259 equity shares under ESOS on 02 June 2026. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 164,959,682/- comprising 164,959,682 equity shares of face value Re.1/- each.

Gland Pharma announced that the 48th Annual General Meeting(AGM) of the company will be held on 25 August 2026.